Thailand to Copy More Patented Cancer Drugs

by Gandhi on September 25, 2007 at 6:20 PM
Thailand to Copy More Patented  Cancer Drugs

Thailand may break more patents of Western drugmakers by adding copycat versions of four cancer medicines into the nation's generic drug programs, a health official said Monday.

The National Health Security Office said it would propose the health ministry issue so-called compulsory licenses on the drugs, unless the government reaches a deal with global pharmaceutical firms to lower prices.


The drugs currently cost Thai patients as much as 100,000 baht (2,920 dollars) per month per person, said Sanguan Nitayarumphong, head of the office that runs a free treatment programme for the poor.

The drugs being targeted include Novartis' Imanitib.

"We might have to impose compulsory licenses of these drugs if negotiations with the patent holders fail," said Sanguan, adding talks have yet to begin.

"The drugs are so expensive for Thai patients. The generic version would provide them greater chance to access the drugs at much cheaper prices."

The drugs that could be affected include Imanitib and Letrozole from Novartis; Docetaxel from Sanofi-Aventis; and Erlotinib from Genentech, he said.

Sanguan said the drugs were essential for Thailand because cancer is a leading cause of death in the kingdom.

Thailand has locked horns with Western pharmaceutical giants by issuing compulsory licenses, which temporarily suspend patent protections, for expensive medications.

The government has so far approved compulsory licenses for Plavix and two key AIDS drugs -- Kaletra and Efavirenz -- and has threatened to expand its generic programs to include cancer drugs.

It has already begun importing cheaper versions from India, a major source of generic drugs.

Plavix, which can help reduce the risks of heart attack or stroke, is sold by French-based Sanofi-Aventis and its US partner, Bristol Myers-Squibb.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Thailand to Copy More Patented Cancer Drugs Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests